Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session
CAMBRIDGE, Mass., Nov. 4, 2025 /PRNewswire/ — Nuvalent, Inc. (Nasdaq:…
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
